Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch
Exelixis Inc · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $50.28
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS